Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lee-Jen Wei, Ph.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department
Title
Institution
Department
Title
Institution
Department

Overview
L.J. Wei's research is in the area of developing statistical methods for the design and analysis of clinical trials. In 1977-78 he introduced the "urn design" for two-arm sequential clinical studies. This design has been utilized in several large-scaled multi-center trials, for example, the Diabetes Control and Complications Trial sponsored by the NIH and the Matching patients to Alcoholism Treatments sponsored by NIAAA.

In 1979, he proposed a response adaptive design, a randomized version of Marvin Zelen's play the winner rule, was used in the ECMO trial, a well-known study which evaluated extracorporeal membrane oxygenation for treating newborns with persistent pulmonary hypertension. Currently several trials sponsored by private industry are using this particular design to relax the ethical problem arising in using the conventional 50-50 randomization treatment allocation rule clinical studies. To monitor trials sequentially for economic and ethical reasons, in 1982 Wei and his colleagues presented a rather flexible monitoring scheme, which has become a classical reference for the literature in interim analysis for clinical trials.

Dr. Wei has developed numerous methods for analyzing data with multiple outcome or repeated measurements obtained from study subjects. In particular, his "multivariate Cox procedures" to handle multiple event times have become quite popular. He and his colleagues are also responsible for developing alternative models to the Cox proportional hazards model for analyzing survival observations.

A very important issue in statistical inference is to check whether the model used to fit the data is appropriate or not. Currently, Wei and his colleagues are developing graphical and numerical methods for checking the adequacy of the Cox proportional hazards model, other semi-parametric survival models, parametric models, and random effects models for repeated measurements. The new procedures are much less subjective than the conventional eye-ball methods based on ordinary residuals plots.

Since the cost of computing has been drastically reduced, some analytically intractable statistical problems can be handled numerically. Presently, Wei and his colleagues are working on various resampling methods for quantile regression, rank regression, and regression models for censored data.

Dr. Wei is also a senior statistician at the Statistical and Data Analysis Center. He works closely with the medical investigators in Pediatrics AIDS clinical trials for evaluating new treatments for HIV patients.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. RC4CA155940 (WEI, LEE-JEN) Sep 30, 2010 - Sep 29, 2013
    NIH/NCI
    Personalized Medicine in Comparative Effectiveness
    Role: Principal Investigator
  2. T32GM074897 (LIN, XIHONG) Jul 1, 2005 - Jun 30, 2020
    NIH/NIGMS
    Interdisciplinary training: Statistical Genetics/Genomics & Computational Biology
    Role: Co-Principal Investigator
  3. R01AI052817 (WEI, LEE-JEN) Sep 30, 2002 - Mar 31, 2005
    NIH/NIAID
    Statistical Methods for HIV/AIDS Studies
    Role: Principal Investigator
  4. R01CA056844 (WEI, LEE-JEN) Aug 15, 1991 - Jul 31, 2001
    NIH/NCI
    SEMIPARAMETRIC METHODS FOR CANCER STUDIES
    Role: Principal Investigator
  5. R01AI029131 (WEI, LEE-JEN) Sep 30, 1989 - Jul 31, 1992
    NIH/NIAID
    STATISTICAL PROBLEMS IN AIDS STUDIES
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. McCaw ZR, Tian L, Wei LJ. Appropriate Analysis of Duration of Response Data in Cancer Trials. JAMA Oncol. 2020 Oct 08. PMID: 33030502.
    Citations:    
  2. McCaw ZR, Tian L, Sheth KN, Hsu WT, Kimberly WT, Wei LJ. Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. Contemp Clin Trials. 2020 Sep 12; 97:106145. PMID: 32927092.
    Citations:    
  3. Ludmir EB, McCaw ZR, Fuller CD, Wei LJ. Progression-free survival in the ICON8 trial. Lancet. 2020 09 12; 396(10253):756. PMID: 32919510.
    Citations:    
  4. Campbell C, Barohn RJ, Bertini E, Chabrol B, Comi GP, Darras BT, Finkel RS, Flanigan KM, Goemans N, Iannaccone ST, Jones KJ, Kirschner J, Mah JK, Mathews KD, McDonald CM, Mercuri E, Nevo Y, Péréon Y, Renfroe JB, Ryan MM, Sampson JB, Schara U, Sejersen T, Selby K, Tulinius M, Vílchez JJ, Voit T, Wei LJ, Wong BL, Elfring G, Souza M, McIntosh J, Trifillis P, Peltz SW, Muntoni F. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020 Oct; 9(14):973-984. PMID: 32851872.
    Citations:    
  5. McCaw ZR, Ludmir EB, Kim DH, Wei LJ. Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet. 2020 08 08; 396(10248):378-379. PMID: 32771102.
    Citations:    
  6. McCaw ZR, Kim DH, Wei LJ. Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. JAMA Oncol. 2020 Aug 01; 6(8):1301-1302. PMID: 32584376.
    Citations:    
  7. McCaw ZR, Kim DH, Wei LJ. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 09 03; 383(10):993. PMID: 32649076.
    Citations:    
  8. McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee CC, Kim DH, Wei LJ. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Ann Intern Med. 2020 Jul 07. PMID: 32634024.
    Citations:    
  9. Huang B, Tian L, McCaw ZR, Luo X, Talukder E, Rothenberg M, Xie W, Choueiri TK, Kim DH, Wei LJ. Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Ann Intern Med. 2020 Sep 01; 173(5):368-374. PMID: 32628533.
    Citations:    
  10. Sun R, Kim DH, Wei LJ. Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Oncol. 2020 Jul 01; 6(7):1121-1122. PMID: 32463424.
    Citations:    
  11. Ludmir EB, McCaw ZR, Kim DH, Tian L, Wei LJ. Fulvestrant plus capivasertib for metastatic breast cancer. Lancet Oncol. 2020 05; 21(5):e233. PMID: 32359498.
    Citations:    
  12. Huang B, Wei LJ, Ludmir EB. Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value. J Clin Oncol. 2020 Jun 10; 38(17):2001-2002. PMID: 32315271.
    Citations:    
  13. Li D, McDonald CM, Elfring GL, Souza M, McIntosh J, Kim DH, Wei LJ. Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. JAMA Netw Open. 2020 02 05; 3(2):e1921306. PMID: 32058550.
    Citations:    
  14. Li D, McCaw ZR, Wei LJ. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older. JAMA Cardiol. 2020 Feb 01; 5(2):235. PMID: 31895431.
    Citations:    
  15. Rabideau DJ, Kim DH, Wei LJ. Using Confidence Intervals to Quantify Statistical and Clinical Evidence for the Treatment Effect in a Comparative Study-Moving Beyond P Values. JAMA Otolaryngol Head Neck Surg. 2020 Jan 01; 146(1):5-6. PMID: 31621806.
    Citations:    
  16. Ludmir EB, McCaw ZR, Grossberg AJ, Wei LJ, Fuller CD. Quantifying the benefit of non-small-cell lung cancer immunotherapy. Lancet. 2019 11 23; 394(10212):1904. PMID: 31777387.
    Citations:    
  17. McCaw ZR, Wei LJ. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JAMA. 2019 10 22; 322(16):1607. PMID: 31638667.
    Citations:    
  18. McCaw ZR, Yin G, Wei LJ. Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation. 2019 10 22; 140(17):1366-1368. PMID: 31634007.
    Citations:    
  19. McCaw ZR, Meng Z, Wei LJ. A Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 09 12; 381(11):e22. PMID: 31509686.
    Citations:    
  20. Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058. PMID: 32337484.
    Citations:    
  21. McCaw ZR, Tian L, Kim DH, Wei LJ. Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)". Ann Surg. 2019 08; 270(2):e48-e50. PMID: 30499804.
    Citations:    
  22. McCaw ZR, Kim DH, Wei LJ. Analysis of Long-term Benefits of Intensive Blood Pressure Control. JAMA. 2019 07 09; 322(2):169-170. PMID: 31287515.
    Citations:    
  23. Manner DH, Battioui C, Hantel S, Beasley BN, Wei LJ, Geiger MJ, Turner JR, Abt M. Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. Am Heart J. 2019 09; 215:178-186. PMID: 31349109.
    Citations:    
  24. Wei LJ, Sun R, Orkaby AR, Kim DH, Zhu H. Biodegradable-polymer stents versus durable-polymer stents. Lancet. 2019 05 11; 393(10184):1932-1933. PMID: 31084958.
    Citations:    
  25. McCaw ZR, Wei LJ, Kim DH. Effects of Aspirin in the Healthy Elderly. N Engl J Med. 2019 05 02; 380(18):1775-1776. PMID: 31042835.
    Citations:    
  26. Claggett B, Uno H, Wei LJ. Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. JAMA Surg. 2019 05 01; 154(5):466-467. PMID: 30785628.
    Citations:    
  27. Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes. 2019 05; 12(5):e005095. PMID: 31109190.
    Citations:    
  28. Zemplenyi M, Wei LJ. Quantifying the Treatment Effect of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy. JAMA Cardiol. 2019 05 01; 4(5):494. PMID: 30916712.
    Citations:    
  29. McCaw ZR, Wei LJ, Kim DH. Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults. JAMA Cardiol. 2019 04 01; 4(4):391. PMID: 30840025.
    Citations:    
  30. McCaw ZR, Wei LJ. Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus. J Clin Oncol. 2019 04 20; 37(12):1032-1033. PMID: 30840522.
    Citations:    
  31. McCaw ZR, Kim DH, Wei LJ. Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. JAMA Cardiol. 2019 03 01; 4(3):299. PMID: 30785598.
    Citations:    
  32. McCaw ZR, Piantadosi S, Wei LJ. Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective. JAMA Surg. 2019 03 01; 154(3):270-271. PMID: 30484814.
    Citations:    Fields:    
  33. McCaw ZR, Vassy JL, Wei LJ. Palbociclib and Fulvestrant in Breast Cancer. N Engl J Med. 2019 02 21; 380(8):796. PMID: 30789681.
    Citations:    
  34. Sun R, Zhu H, Wei LJ. Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer. JAMA Oncol. 2019 02 01; 5(2):270. PMID: 30543368.
    Citations:    Fields:    
  35. McCaw ZR, Kim DH, Tian L, Fu H, Wei LJ. Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncol. 2019 01; 20(1):e8. PMID: 30614483.
    Citations:    Fields:    
  36. McCaw ZR, Jiang F, Wei LJ. Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JAMA Oncol. 2019 01 01; 5(1):117-118. PMID: 30520963.
    Citations:    Fields:    
  37. Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease. J Alzheimers Dis. 2019; 67(2):555-570. PMID: 30530975.
    Citations:    Fields:    
  38. Sun R, Lee H, Wei LJ. Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma. JAMA Surg. 2019 01 01; 154(1):96. PMID: 30427976.
    Citations:    Fields:    
  39. McCaw ZR, Liu D, Wei LJ. Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2019 01 01; 5(1):114-115. PMID: 30476943.
    Citations:    Fields:    
  40. Sun R, Wei LJ. Regional Hyperthermia With Neoadjuvant Chemotherapy for Treatment of Soft Tissue Sarcoma. JAMA Oncol. 2019 01 01; 5(1):112-113. PMID: 30489612.
    Citations:    Fields:    
  41. Sun R, Nie L, Huang B, Kim DH, Wei LJ. Quantifying Immunoscore performance. Lancet. 2018 11 03; 392(10158):1624. PMID: 30496077.
    Citations:    Fields:    Translation:HumansCells
  42. Claggett B, Tian L, Wei LJ. Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. JAMA Oncol. 2018 11 01; 4(11):1617-1618. PMID: 30098159.
    Citations:    Fields:    
  43. McCaw ZR, Wei LJ, Kim DH. Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer. N Engl J Med. 2018 Oct 25; 379(17):1681. PMID: 30358968.
    Citations:    Fields:    Translation:Humans
  44. Orkaby AR, Rich MW, Sun R, Lux E, Wei LJ, Kim DH. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc. 2018 10; 66(10):1987-1991. PMID: 30251369.
    Citations:    Fields:    
  45. Sun R, Rich MW, Wei LJ. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018 09 13; 379(11):e18. PMID: 30211499.
    Citations:    Fields:    Translation:Humans
  46. McCaw ZR, Orkaby AR, Wei LJ, Kim DH, Rich MW. Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time. Am J Med. 2019 01; 132(1):13-15. PMID: 30076822.
    Citations:    Fields:    
  47. Claggett B, Tian L, McCaw ZR, Takeuchi M, Wei LJ. Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e377. PMID: 30102227.
    Citations:    Fields:    
  48. Uno H, Tian L, Wei LJ. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. JAMA Oncol. 2018 08 01; 4(8):1137-1138. PMID: 29931103.
    Citations:    Fields:    
  49. Uno H, Kim DH, Wei LJ. Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncol. 2018 08 01; 4(8):1135-1136. PMID: 29902302.
    Citations:    Fields:    
  50. Claggett B, Tian L, Fu H, Solomon SD, Wei LJ. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. Stat Med. 2018 11 10; 37(25):3589-3598. PMID: 30047148.
    Citations:    Fields:    
  51. Huang B, Tian L, Talukder E, Rothenberg M, Kim DH, Wei LJ. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. JAMA Oncol. 2018 06 01; 4(6):874-876. PMID: 29710201.
    Citations:    Fields:    
  52. Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. JAMA Oncol. 2018 06 01; 4(6):881-882. PMID: 29801103.
    Citations:    Fields:    
  53. Fang X, Uno H, Wei LJ. Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors. JAMA Oncol. 2018 05 01; 4(5):743. PMID: 29372245.
    Citations:    Fields:    
  54. Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, Wei LJ. Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. Ann Oncol. 2018 05 01; 29(5):1092-1094. PMID: 29617717.
    Citations: 1     Fields:    
  55. Zhao L, Tian L, Claggett B, Pfeffer M, Kim DH, Solomon S, Wei LJ. Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. JAMA Cardiol. 2018 04 01; 3(4):357-358. PMID: 29541747.
    Citations:    Fields:    
  56. Hasegawa T, Uno H, Wei LJ. Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018 04 01; 4(4):585. PMID: 29192309.
    Citations:    Fields:    
  57. Sun R, Horiguchi M, Wei LJ. Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival. J Clin Oncol. 2018 05 01; 36(13):1378-1379. PMID: 29558278.
    Citations:    Fields:    
  58. Angelidou K, Palumbo P, Lindsey J, Violary A, Archary M, Barlow L, Claggett B, Hughes M, Wei LJ. Defining Study Outcomes That Better Reflect Individual Response to Treatment. Pediatr Infect Dis J. 2018 03; 37(3):258-262. PMID: 29189677.
    Citations:    Fields:    Translation:HumansCells
  59. Horiguchi M, Uno H, Wei LJ. Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. J Clin Oncol. 2018 03 10; 36(8):825-826. PMID: 29373099.
    Citations:    Fields:    
  60. Uno H, Hassett MJ, Wei LJ. Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306. PMID: 29340668.
    Citations:    Fields:    Translation:Humans
  61. Horiguchi M, Uno H, Wei LJ. Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. J Clin Oncol. 2018 03 01; 36(7):720-721. PMID: 29337638.
    Citations:    Fields:    
  62. Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncol. 2017 12 01; 3(12):1692-1696. PMID: 28975263.
    Citations: 3     Fields:    
  63. Kim DH, Uno H, Wei LJ. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiol. 2017 11 01; 2(11):1179-1180. PMID: 28877311.
    Citations: 4     Fields:    
  64. Cheng D, Pak K, Wei LJ. Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. JAMA Oncol. 2017 10 01; 3(10):1430-1431. PMID: 28750125.
    Citations: 1     Fields:    
  65. Tian L, Fu H, Ruberg SJ, Uno H, Wei LJ. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biometrics. 2018 06; 74(2):694-702. PMID: 28901017.
    Citations: 3     Fields:    
  66. Horiguchi M, Uno H, Wei LJ. Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. J Clin Oncol. 2017 10 10; 35(29):3373. PMID: 28800271.
    Citations:    Fields:    
  67. Hasegawa T, Uno H, Wei LJ. How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? J Clin Oncol. 2016 11 01; 34(31):3818. PMID: 27507875.
    Citations: 1     Fields:    Translation:Humans
  68. Hasegawa T, Uno H, Wei LJ. Safety Study of Salmeterol in Asthma in Adults. N Engl J Med. 2016 09 15; 375(11):1097. PMID: 27626533.
    Citations:    Fields:    Translation:Humans
  69. Hasegawa T, Uno H, Wei LJ. Neratinib after trastuzumab in patients with HER2-positive breast cancer. Lancet Oncol. 2016 05; 17(5):e176. PMID: 27301038.
    Citations:    Fields:    Translation:Humans
  70. Hasegawa T, Uno H, Wei LJ. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2016 02 04; 374(5):492-3. PMID: 26840145.
    Citations: 1     Fields:    Translation:Humans
  71. Li J, Zhao L, Tian L, Cai T, Claggett B, Callegaro A, Dizier B, Spiessens B, Ulloa-Montoya F, Wei LJ. A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. Biometrics. 2016 09; 72(3):877-87. PMID: 26689167.
    Citations: 6     Fields:    Translation:Humans
  72. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21; 163(2):127-34. PMID: 26054047.
    Citations: 13     Fields:    Translation:Humans
  73. Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, McHutchison JG. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):772-9.e1-3. PMID: 25528010.
    Citations: 32     Fields:    Translation:Humans
  74. Claggett B, Tian L, Castagno D, Wei LJ. Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. Biostatistics. 2015 Jan; 16(1):60-72. PMID: 25122189.
    Citations: 5     Fields:    Translation:Humans
  75. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 01; 32(22):2380-5. PMID: 24982461.
    Citations: 36     Fields:    Translation:Humans
  76. Uno H, Wei LJ, Hughes M. Effects of bracing in adolescents with idiopathic scoliosis. N Engl J Med. 2014 02 13; 370(7):680. PMID: 24521129.
    Citations:    Fields:    Translation:Humans
  77. Claggett B, Wei LJ, Pfeffer MA. Moving beyond our comfort zone. Eur Heart J. 2013 Mar; 34(12):869-71. PMID: 23329152.
    Citations: 4     Fields:    Translation:Humans
  78. Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012 Oct; 9(5):570-7. PMID: 22914867.
    Citations: 14     Fields:    Translation:Humans
  79. Tian L, Cai T, Zhao L, Wei LJ. On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial. Biostatistics. 2012 Apr; 13(2):256-73. PMID: 22294672.
    Citations: 9     Fields:    Translation:Humans
  80. Claggett B, Wei LJ. Analytical issues regarding rosiglitazone meta-analysis. Arch Intern Med. 2011 Jan 24; 171(2):179-80; author reply 180. PMID: 21263111.
    Citations: 1     Fields:    Translation:Humans
  81. Tian L, Wang R, Cai T, Wei LJ. The highest confidence density region and its usage for joint inferences about constrained parameters. Biometrics. 2011 Jun; 67(2):604-10. PMID: 20825392.
    Citations: 1     Fields:    
  82. Li Y, Tian L, Wei LJ. Estimating subject-specific dependent competing risk profile with censored event time observations. Biometrics. 2011 Jun; 67(2):427-35. PMID: 20618311.
    Citations: 3     Fields:    Translation:Humans
  83. Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, Wei LJ, Sunyaev SR. Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet. 2010 Jun 11; 86(6):832-8. PMID: 20471002.
    Citations: 385     Fields:    Translation:Humans
  84. Elkayam U, Janmohamed M, Hatamizadeh P, Heywood JT, Wei LJ, Mills RM. Impact of acute serum creatinine elevation in patients treated with nesiritide. Clin Cardiol. 2009 Apr; 32(4):215-9. PMID: 19353723.
    Citations: 1     Fields:    Translation:Humans
  85. Zhou H, Wei LJ, Xu X, Xu X. Combining association tests across multiple genetic markers in case-control studies. Hum Hered. 2008; 65(3):166-74. PMID: 17940337.
    Citations: 1     Fields:    Translation:Humans
  86. Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig. 2007; 27(1):35-49. PMID: 17177578.
    Citations: 8     Fields:    Translation:Humans
  87. Feng Y, Hong X, Li Z, Zhang W, Jin D, Liu X, Zhang Y, Hu FB, Wei LJ, Zang T, Xu X, Xu X. Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. Obesity (Silver Spring). 2006 Nov; 14(11):2089-98. PMID: 17135627.
    Citations: 23     Fields:    Translation:Humans
  88. Wang L, Feng Y, Zhang Y, Zhou H, Jiang S, Niu T, Wei LJ, Xu X, Xu X, Wang X. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol. 2006 Jul; 195(1):162-71. PMID: 16681991.
    Citations: 17     Fields:    Translation:Humans
  89. Hughes WT, Dankner WM, Yogev R, Huang S, Paul ME, Flores MA, Kline MW, Wei LJ. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis. 2005 Jan 01; 40(1):136-45. PMID: 15614703.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  90. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. . 2004 Jul 01; 36(3):772-6. PMID: 15213559.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  91. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004 May 22; 20(8):1233-40. PMID: 14871870.
    Citations: 157     Fields:    Translation:Humans
  92. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004 Jan 01; 64(1):64-71. PMID: 14729609.
    Citations: 54     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Wei's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (293)
Explore
_
Co-Authors (31)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.